Cargando…

Tivozanib in renal cell carcinoma: a new approach to previously treated disease

Targeted therapies have been a mainstay of the renal cell carcinoma (RCC) treatment paradigm for the better part of two decades. Multikinase inhibitors of the vascular endothelial growth factor receptor tyrosine kinases (VEGF-TKIs) comprise nearly all targeted therapies in RCC, having been prospecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Salgia, Nicholas J., Zengin, Zeynep B., Pal, Sumanta K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249546/
https://www.ncbi.nlm.nih.gov/pubmed/32547647
http://dx.doi.org/10.1177/1758835920923818
_version_ 1783538607125954560
author Salgia, Nicholas J.
Zengin, Zeynep B.
Pal, Sumanta K.
author_facet Salgia, Nicholas J.
Zengin, Zeynep B.
Pal, Sumanta K.
author_sort Salgia, Nicholas J.
collection PubMed
description Targeted therapies have been a mainstay of the renal cell carcinoma (RCC) treatment paradigm for the better part of two decades. Multikinase inhibitors of the vascular endothelial growth factor receptor tyrosine kinases (VEGF-TKIs) comprise nearly all targeted therapies in RCC, having been prospectively tested through large, multi-institutional phase III trials. Tivozanib is a VEGF-TKI with high selectivity for VEGF receptors 1–3. Tivozanib has been under investigation for nearly 15 years, with a robust portfolio of preclinical and clinical data. This review seeks to characterize tivozanib within the context of RCC by highlighting preclinical and early clinical trials alongside the phase III trials in RCC, TIVO-1, and TIVO-3. We also aim to explore further trials of tivozanib, whether in combination with other agents and/or in differing disease settings, while providing insight into the utility of tivozanib as a clinical tool for the management of RCC.
format Online
Article
Text
id pubmed-7249546
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-72495462020-06-15 Tivozanib in renal cell carcinoma: a new approach to previously treated disease Salgia, Nicholas J. Zengin, Zeynep B. Pal, Sumanta K. Ther Adv Med Oncol Challenging Dogma: New Evidence to Guide Practice in Urologic Oncology Targeted therapies have been a mainstay of the renal cell carcinoma (RCC) treatment paradigm for the better part of two decades. Multikinase inhibitors of the vascular endothelial growth factor receptor tyrosine kinases (VEGF-TKIs) comprise nearly all targeted therapies in RCC, having been prospectively tested through large, multi-institutional phase III trials. Tivozanib is a VEGF-TKI with high selectivity for VEGF receptors 1–3. Tivozanib has been under investigation for nearly 15 years, with a robust portfolio of preclinical and clinical data. This review seeks to characterize tivozanib within the context of RCC by highlighting preclinical and early clinical trials alongside the phase III trials in RCC, TIVO-1, and TIVO-3. We also aim to explore further trials of tivozanib, whether in combination with other agents and/or in differing disease settings, while providing insight into the utility of tivozanib as a clinical tool for the management of RCC. SAGE Publications 2020-05-22 /pmc/articles/PMC7249546/ /pubmed/32547647 http://dx.doi.org/10.1177/1758835920923818 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Challenging Dogma: New Evidence to Guide Practice in Urologic Oncology
Salgia, Nicholas J.
Zengin, Zeynep B.
Pal, Sumanta K.
Tivozanib in renal cell carcinoma: a new approach to previously treated disease
title Tivozanib in renal cell carcinoma: a new approach to previously treated disease
title_full Tivozanib in renal cell carcinoma: a new approach to previously treated disease
title_fullStr Tivozanib in renal cell carcinoma: a new approach to previously treated disease
title_full_unstemmed Tivozanib in renal cell carcinoma: a new approach to previously treated disease
title_short Tivozanib in renal cell carcinoma: a new approach to previously treated disease
title_sort tivozanib in renal cell carcinoma: a new approach to previously treated disease
topic Challenging Dogma: New Evidence to Guide Practice in Urologic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249546/
https://www.ncbi.nlm.nih.gov/pubmed/32547647
http://dx.doi.org/10.1177/1758835920923818
work_keys_str_mv AT salgianicholasj tivozanibinrenalcellcarcinomaanewapproachtopreviouslytreateddisease
AT zenginzeynepb tivozanibinrenalcellcarcinomaanewapproachtopreviouslytreateddisease
AT palsumantak tivozanibinrenalcellcarcinomaanewapproachtopreviouslytreateddisease